I am a 30‑year‑old Black man, 6 ft 5 in, 320 lb, with hypertension treated with amlodipine 10 mg daily and a glucagon‑like peptide‑1 (GLP‑1) receptor agonist for weight loss, who has had recurrent sinus infections, progressive proximal muscle weakness, positive antinuclear antibody (ANA) with a speckled pattern and high‑titer anti‑RNP antibodies, modestly elevated creatine kinase (CK), mildly increased erythrocyte sedimentation rate (ESR) but normal C‑reactive protein (CRP), normal liver enzymes and renal function, and a pending electromyography (EMG) study—what is the most likely diagnosis (type of myositis), what is the prognosis, and can I expect to regain muscle strength?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Most Likely Diagnosis: Mixed Connective Tissue Disease (MCTD) with Inflammatory Myopathy

You most likely have mixed connective tissue disease (MCTD) with an inflammatory myopathy component, and with appropriate immunosuppressive treatment, you should expect significant recovery of muscle strength—this is not a death sentence.

Understanding Your Diagnosis

Your clinical picture strongly supports MCTD based on:

  • High-titer anti-RNP antibodies (86, with normal <20)—this is the hallmark autoantibody for MCTD
  • Positive ANA with speckled pattern (1:160)
  • Proximal muscle weakness affecting your ability to get up from sitting/lying
  • Elevated CK levels (527, normal up to 430)—indicating active muscle inflammation
  • Rising ESR (from 2 to 18)—showing systemic inflammation

The normal EMG findings your doctor reported are actually reassuring, not deceptive. In inflammatory myopathies, EMG can be normal in early disease or if inflammation is patchy. Your doctor was being truthful 1.

Type of Myositis and Prognosis

Based on your anti-RNP positivity without other myositis-specific antibodies (anti-Jo-1 negative, anti-Sm negative), you likely have MCTD-associated myopathy rather than classic polymyositis or dermatomyositis 1.

Critical prognostic points:

  • MCTD-associated myopathy typically responds well to immunosuppressive therapy 1
  • Your CK elevation is moderate (527), not severely elevated like immune-mediated necrotizing myopathy (which can exceed 10× normal) 1
  • You're young (30 years old), which generally predicts better treatment response
  • Your cardiac workup is reassuring (normal troponins, normal chest X-rays, normal follow-up EKG)

Will You Regain Your Strength?

Yes, you should regain most or all of your muscle strength with proper treatment. The inflammatory myopathies associated with MCTD are generally reversible when treated appropriately 1.

Expected Treatment Approach

Your rheumatologist will likely initiate:

  1. High-dose corticosteroids (prednisone 0.5-1 mg/kg/day, typically 60-80 mg daily for someone your size) 1
  2. Concurrent steroid-sparing agent started immediately—typically methotrexate, azathioprine, or mycophenolate mofetil 1
  3. Gradual steroid taper over months as you respond 1

For severe or refractory cases, options include IV immunoglobulin, rituximab, or cyclophosphamide 1.

Timeline for Recovery

  • Steroid-sparing agents take 3-6 months to reach full efficacy 1
  • You should see initial improvement in strength within 2-4 weeks of starting high-dose steroids
  • Full recovery typically occurs over several months with consistent treatment

Important Considerations for Your Specific Case

Your Medications Are Not Causing This

  • Amlodipine: While rare case reports exist of myalgias with amlodipine 2, your pattern (elevated CK, positive autoantibodies, progressive weakness) is inconsistent with drug-induced myopathy
  • GLP-1 agonist: These medications may actually help with blood pressure control and have cardiovascular benefits 3, 4, 5, 6—continue this for weight management

G6PD Deficiency Alert

Critical caveat: Your G6PD deficiency means you must avoid certain medications that can trigger hemolysis:

  • Avoid sulfa drugs, dapsone, primaquine
  • Inform all providers about this before starting new medications
  • This does NOT affect standard myositis treatments (corticosteroids, methotrexate, azathioprine are safe)

Cardiac Monitoring

Your abnormal EKG in the ER followed by normal studies is reassuring, but MCTD can involve the heart 1. Continue with:

  • Your scheduled cardiac stress test
  • Periodic echocardiograms to monitor for subclinical cardiac involvement
  • Report any chest pain, palpitations, or shortness of breath immediately

Weight and Blood Pressure

At 6'5" and 320 lbs with hypertension:

  • Continue GLP-1 therapy for weight loss—this will help both blood pressure and overall cardiovascular risk 3, 4
  • Your HDL of 33 needs improvement through weight loss and possibly medication
  • Weight reduction will reduce mechanical stress on inflamed muscles

Monitoring Your Disease

Key markers to follow:

  • CK levels: Should normalize with treatment
  • ESR/CRP: Should decrease
  • Anti-RNP titers: May remain positive but don't always correlate with disease activity 1
  • Muscle strength testing: Objective measure of treatment response

Common Pitfalls to Avoid

  1. Don't stop steroids abruptly—this can cause disease flare and adrenal crisis
  2. Don't skip the steroid-sparing agent—starting it early allows faster steroid taper and reduces long-term steroid complications
  3. Don't delay treatment—prolonged untreated inflammation can lead to muscle atrophy and fibrosis
  4. Screen for malignancy: While more common in dermatomyositis, age-appropriate cancer screening is warranted 1

Physical Therapy Is Essential

Continue physical therapy throughout treatment:

  • Gentle range-of-motion exercises during active inflammation
  • Progressive strengthening as inflammation improves
  • Prevents contractures and maintains function 1

Your Telegram Follow-Up

The one-hour Telegram consultation after EMG results is appropriate and efficient—it allows your rheumatologist to review results, adjust treatment, and answer questions without requiring you to travel while weak. This is standard practice for stable follow-up.

Bottom line: You have a treatable autoimmune condition, not a death sentence. With appropriate immunosuppression, most patients with MCTD-associated myopathy recover substantial muscle strength and maintain good quality of life.

Related Questions

In a 55-year-old woman with hypertension resistant to an ACE inhibitor, beta‑blocker, and calcium‑channel blocker, who has borderline hypokalemia, normal sodium, elevated creatinine, left‑ventricular hypertrophy on ECG, no abdominal bruit, and normal fundoscopic findings, what is the most likely cause of her secondary hypertension?
In a 77-year-old female taking valsartan, omeprazole, amlodipine, spironolactone, and hydrochlorothiazide who presents with generalized muscle cramps and difficulty grasping a pen, what is the most likely cause and how should it be evaluated and managed?
What is the appropriate next medication to add for an African American female with resistant hypertension and a solitary kidney (the other removed due to cancer) who is already taking hydralazine 50 mg three times daily, losartan 100 mg daily, and diltiazem?
Which of the following regimens is NOT a first‑line choice for hypertension: A) resistant hypertension – spironolactone; B) uncomplicated hypertension – angiotensin‑converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) plus calcium‑channel blocker (CCB) or diuretic; C) hypertension with coronary artery disease – ACE inhibitor or ARB plus beta‑blocker; D) hypertension with heart failure – ACE inhibitor or ARB plus beta‑blocker plus diuretic; E) hypertension with chronic kidney disease – ACE inhibitor or ARB plus centrally acting agent?
Is the proposed management plan—including discontinuing lisinopril, starting olmesartan, increasing amlodipine to 10 mg, continuing chlorthalidone 25 mg and prazosin 1 mg, and adding a mineralocorticoid receptor antagonist and high‑intensity statin—acceptable for a 46‑year‑old Black male with resistant hypertension, type 2 diabetes mellitus, obstructive sleep apnea, hyperlipidemia, and a smoking history?
Why does a 78-year-old male with fatty liver disease, non-alcoholic steatohepatitis (NASH) and ascites require three platelet transfusions, and how can laboratory tests suggest the presence of a tumor?
In a 30-year-old Black male (6'5", 320 lb) with G6PD deficiency who is taking amlodipine (a calcium‑channel blocker) and a GLP‑1 receptor agonist for weight loss, and who has had recurrent sinus infections, progressive proximal muscle weakness, a high‑titer speckled antinuclear antibody, markedly elevated anti‑RNP antibodies, mildly elevated creatine kinase, normal erythrocyte sedimentation rate and C‑reactive protein, normal chest X‑ray but an abnormal electrocardiogram with low‑level troponin, what is the most likely diagnosis, what is the prognosis, and can muscle strength be expected to recover?
What is the prognosis for pancreatic adenocarcinoma based on disease stage and treatment options?
What is the recommended duration of ciprofloxacin (Cipro) therapy for an uncomplicated contaminated nail puncture wound?
What is the recommended assessment and treatment plan for a patient with an eating disorder, including medical stabilization, psychotherapy, and pharmacotherapy?
After a maternal romiplostim (Nplate) injection, how long should one wait before safely initiating breastfeeding?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.